Abstract
Moxifloxacin is an 8-methoxy-fluoroquinolone antibiotic with a broad spectrum of activity. Its in vitro activity and pharmacodynamic properties make it a useful agent for the treatment of community-acquired respiratory tract infections. In clinical trials, oral moxifloxacin has shown similar efficacy to clarithromycin and high-dose amoxicillin for community-acquired pneumonia; clarithromycin and azithromycin for acute exacerbations of chronic bronchitis; cefuroxime axetil for sinusitis; and cephalexin for uncomplicated skin and skin structure infections. There are minimal published data regarding the use of moxifloxacin for nosocomial infections, infections caused by anaerobic organisms, or for treatment of any infections with the intravenous formulation. Overall, moxifloxacin is well-tolerated with a drug interaction and safety profile similar to that of other fluoroquinolones.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-26 |
| Number of pages | 26 |
| Journal | Journal of Infectious Disease Pharmacotherapy |
| Volume | 6 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2003 |
| Externally published | Yes |
Keywords
- Acute exacerbations of chronic bronchitis
- Community-acquired pneumonia
- Fluoroquinolone
- Moxifloxacin
- Sinusitis
ASJC Scopus subject areas
- Pharmacology
- Microbiology (medical)